2 Growth Catalysts Could Push Arena Pharmaceuticals, Inc. (ARNA) Higher In 2013

Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) slumped after the company said EU regulators still have questions about its weight-loss drug Belviq.

What Happened?

An advisory committee to the European Medicines Agency has asked for more information on heart valve issues, psychiatric side effects, and tumors that were detected during studies on rats. The advisory panel also asked the company to provide a risk/ benefit analysis on Belviq. Arena had asked EU regulators to approve Belviq in March 2012, and it has been addressing concerns raised by regulators in its endeavor to win marketing clearance. Arena expects the advisory committee to issue a recommendation during the first half of 2013. The U.S. Food & Drug Administration (FDA) approved Belviq in late June 2012. Arena and its partner Eisai Co., Ltd (ADR) (NASDAQOTH: ESALY) are not yet working on plans to launch in the U.S. market. Eisai is a global manufacturer of pharmaceutical products based in Tokyo, Japan. With $2.4 billion in cash and short-term investments, Eisai is in a good position to help support Belviq. Eisai recently granted an additional six months of market exclusivity in the U.S. for Aciphex due to the ruling that Eisai has met the FDA’s Written Request requirements for pediatric exclusivity for the drug. Aciphex provides short-term treatment for heartburn, duodenal ulcers, and gastroesophageal reflux disease.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)The FDA approved VIVUS, Inc. (NASDAQ:VVUS)’ Qsymia around the same time it approved Belviq. Qsymia was launched in the U.S. before the end of 2012. Vivus is also developing Qsymia to treat sleep apnea and diabetes. Both of these development programs are now in Phase 2 trials. There has been talk of Vivus being bought out by a larger pharmaceutical such as Bristol Myers Squibb Co. (NYSE:BMY)AstraZeneca plc (ADR) (NYSE:AZN) or Eli Lilly & Co. (NYSE:LLY), all of which are looking for a potential blockbuster drug to add to their pipelines.

Jefferies & Co. analyst Thomas Wei believes that Arena shares could be volatile because of investor uncertainty about the EU approval and pessimism about the sales potential of Belviq. Wei also says he is more bullish about the prospects of a combination of Belviq and phentermine.

The Possibility of Rejection in Europe

There is no way of predicting how the regulatory process will play out, but there are several factors that should be considered. The FDA considers Belviq to be safe. It did not require a REMS program, and the CHMP advisory committee recommendation should be available in the first half of this year, with approval following within a few months if the recommendation is favorable. This could potentially be a big advantage for the treatment because it could make Arena the only player in a huge market. Qsymia was recently rejected in the EU and an appeal against this decision is unlikely to succeed. The January CHMP meeting has ended without any action on Belviq.

Arena has disclosed the 180-day list of questions about Belviq raised by European regulators, and the list raises some difficult questions. The issues will need to be resolved before the CHMP can make a positive recommendation for marketing approval in the EU. The company says that the major objections relate to previously identified non-clinical and clinical issues, including tumors in rats, valvulopathy and psychiatric events. The CHMP further requests that it justifies Belviq’s overall balance of benefit-risk after taking these issues into consideration. In accordance with the CHMP’s process, the company has been asked to address the issues in writing. The CHMP will also consult with independent experts who will provide recommendations on the outstanding issues. Some of these concerns were raised in the 120-day list of questions from the European regulators, which indicates that the company’s responses were not entirely to their satisfaction.

Arena had already advised investors about Europe’s more stringent approval criteria for weight-loss treatments compared to the U.S. For instance, the EMA guidelines provide that clinical trials assessing drug candidates intended for weight control should subject patients to a weight reducing diet run-in period. Its Phase 3 clinical trials did not include this requirement. EMA guidelines also prescribe primary and alternative primary efficacy criteria for weight loss drug candidates. The company believes that Belviq will satisfy the EMA’s alternative primary efficacy criterion, which measures the proportion of responders achieving more than 10% weight loss at the end of a 12-month period. However, Belviq is unlikely to meet the more stringent EMA primary efficacy criterion, which prescribes a demonstration of weight loss of at least 10% of baseline weight that is also at least 5% greater than the loss associated with the placebo.

Belviq’s placebo-adjusted weight loss from its trials was 3%, well below Europe’s primary efficacy criterion. The FDA had concerns similar to European regulators about the safety and efficacy of Belviq last year. Arena was able to satisfy the FDA concerns sufficiently enough to gain approval, but this should not be seen as a certainty of approval in Europe. On a risk/benefit basis, Vivus had strong data for Qsymia, yet the application was rejected in Europe.

Conclusion

The delay in Europe is not by any means the end of the world, and the next price catalyst for the stock will almost certainly be a successful launch of Belviq in the U.S. Arena has Eisai as a marketing partner for Belviq, and the presence of a strong partner will give the company an advantage over Vivus. The weak launch by Vivus puts less competitive pressure on the company and plenty of space to make a strong initial launch.

Analysts have low expectations of initial sales. Jeffries lowered its 2013 sales forecast by 70%. An analyst at JPMorgan forecast sales of $74 million for 2013 growing to $481 million in 2016.  A strong performance will provide strong upside for the stock. I recommend buying Arena with the expectation of two upcoming growth catalysts – a successful U.S. launch followed by approval in Europe.

The article 2 Growth Catalysts Could Push This Pharmaceutical Higher In 2013 originally appeared on Fool.com and is written by Jordo Bivona.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

Top 6 Cities For The Ultra Rich to Live in Comfort

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!